REBOOT试验:心肌梗死后β受体阻滞剂的性别差异效应
REBOOT试验的预设性别亚组分析纳入8438例LVEF>40%的急性心梗患者,比较β受体阻滞剂与不用药。
要点
- 女性心梗后LVEF>40%使用β受体阻滞剂与主要终点风险增加相关(HR 1.45)。
- 女性中风险增加主要由死亡驱动,LVEF保留和高剂量者更明显。
核心结论
- 在REBOOT试验中,β受体阻滞剂治疗与女性心肌梗死后证据性危害相关,尤其LVEF保留和接受较高剂量者,而男性未观察到该效应。
研究设计与样本
- REBOOT试验的预设性别亚组分析,纳入8505例随机患者中8438例意向性治疗人群,评估急性心梗且LVEF>40%患者使用β受体阻滞剂的效果。
主要发现
- 女性主要复合终点(死亡、心梗或心衰住院)发生率在β受体阻滞剂组为30.4/1000患者年,不用药组为21.0/1000患者年(HR 1.45,95%CI 1.04-2.03)。
临床怎么用
- 对于心肌梗死后LVEF>40%的女性患者,处方β受体阻滞剂需权衡潜在危害,尤其LVEF保留和考虑较高剂量时。
- 男性患者中β受体阻滞剂的使用可参考现有证据,但需结合个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Recent trials have challenged the guideline recommendation of beta-blockers for post-myocardial infarction (MI) patients without reduced left ventricular ejection fraction (LVEF). Whether these recent findings apply equally to women and men remains unknown. METHODS: Using data from REBOOT (tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion), the largest randomized trial evaluating the effect of beta-blockers after acute MI with LVEF > 40%, a pre-specified sex-specific subgroup analysis was performed. A total of 8438 out of the 8505 randomized patients comprised the intention-to-treat population. RESULTS: Among 8438 patients, 1627 were women, who were older, had more comorbidities, and received fewer guideline-based therapies than men. Over a median follow-up of 3.7 years, women had overall higher rates of the primary composite outcome (death, MI, or heart failure hospitalization) than men. The incidence rate of the primary endpoint in women was 30.4 and 21.0/1000 patient-years in the beta-blocker group and no beta-blocker group, respectively (hazard ratio 1.45, 95% confidence interval 1.04-2.03). No significant differences were observed in men (hazard ratio .94, 95% confidence interval .79-1.13; P for interaction = .026). The excess risk in women was mainly driven by increased mortality and was most evident among those with preserved LVEF (P for interaction = .030) and those receiving higher beta-blocker doses (P for interaction = .045). CONCLUSIONS: In the REBOOT trial of MI patients managed according to contemporary standards, beta-blocker therapy was associated with evidence of harm in women-particularly those with preserved LVEF and receiving higher doses-an effect not observed in men.
引用
- Rossello, Dominguez-Rodriguez, Latini, et al. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Eur Heart J. 2026. PMID: 40884211. doi:10.1093/eurheartj/ehaf673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。